No, Ajanta Pharma is not debt free. According to the company’s 2019 annual report, the company had a total debt of around ₹3,955 million at the end of the year, with long-term debt accounting for a significant portion of this amount.
As of March 31, 2020, the company’s total debt has grown to ₹5,527. 26 million. On the other hand, its cash and cash equivalents have dropped to ₹236. 20 million from ₹682. 88 million in the same period.
Thus, AJANTPHARM is not totally debt free.
Table of Contents
Is Ajanta Pharma a good investment?
Whether or not Ajanta Pharma is a good investment depends on a variety of factors such as your investment goals, risk tolerance, and analysis of the company’s market performance. From a fundamental analysis perspective, the company has consistently grown its revenues, earnings, and operating margins.
It has gradually increased its market share in the domestic and global markets. It has a broad product portfolio and a focus on innovation and new product launches. Its balance sheet management has also been quite prudent, maintaining a healthy debt to equity ratio.
Additionally, it has a strong presence in several high potential therapeutic segments as well as a well-established research and development facility.
On the other hand, from a market perspective, there is ongoing price competition that is increasingly making it difficult for it to maintain margins. In addition, ever-evolving government regulations could bring uncertainty to its future business prospects.
Hence, it is worth doing an in-depth analysis of the company and its market before investing in it. Ultimately, if the fundamental analysis is aligned with your goals and expected return, Ajanta Pharma could present an interesting investment opportunity.
What is the rank of Ajanta Pharma?
Ajanta Pharma is a top-ranked pharmaceutical company in India. They strive to bring high-quality, reliable, and affordable medicines to a wide range of patients around the world. Founded in 1973, Ajanta Pharma has grown to become one of the leading and trusted manufacturers and exporters of pharmaceutical products.
They open new R&D centres, constantly innovate and work on pioneering drugs, and ensure a sustained manufacturing process with a relentless push for technological advancements. Ajanta Pharma is listed on both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of 2021, Ajanta Pharma ranks at 1178 on the BSE index and is 303rd on the NSE index.
Which Pharma share is investment?
Investment in pharma share can be a great way to diversify your portfolio. Pharma stocks generally tend to outperform the market, which makes them attractive to investors. The largest pharma companies have established products and long records of stable profits, enabling them to weather the ups and downs of the stock market.
When investing in pharma shares, a dividend investor should look for large companies with established products, research and development capabilities and experienced management teams. Popular pharma stocks include names such as Johnson & Johnson, Novartis, AstraZeneca, Merck & Co, Pfizer and AbbVie.
Additionally, biotech companies such as Gilead Sciences, Celgene, Amgen, and Biogen can offer investors potential for capital appreciation. Before investing in pharma stocks, it is important for investors to do their research and understand the sector and the company specific risk factors.
Which is the largest drug company in India by market cap?
The largest drug company in India by market cap is Sun Pharmaceutical Industries (Sun Pharma). Established in 1983, it is one of the largest pharma companies in India and the fifth-largest in the world, with a market cap of around $38.
5 billion as of 2020. It has grown over the years to become a multi-national company with presence in over 150 countries and a wide portfolio that includes specialty, generic, branded, and over-the-counter products covering several therapeutic areas.
Sun Pharma’s strong financial performance, combined with its commitment to developing innovative products, have enabled it to become the largest drug company in India.
Which stocks are Large Cap in India?
Large Cap stocks in India are those that have a market capitalisation value of over Rs. 10,000 crore. Some of the most popular Large Cap stocks in India include Reliance Industries, Tata Consultancy Services, HDFC Bank, Hindustan Unilever, ICICI Bank, Infosys, SBI, and Larsen & Toubro.
These stocks are known to have high liquidity and have a low risk profile, making them attractive for investors. Other Large Cap stocks in India include HCL Technologies, Bajaj Auto, TCS, ITC, Wipro, and Maruti Suzuki.
Investing in Large Cap stocks can provide stable returns, but they are also more expensive compared to their peers. Therefore, they should be carefully analyzed before investing in them.
Which is the biggest pharma hub in India?
Mumbai is India’s biggest pharma hub. The city is home to some of India’s biggest pharma companies such as Cipla, Lupin, Wockhardt, Cadila, Dr Reddys and Glenmark. The pharma industry in India is highly regulated, so companies operating in any sector of the pharma industry need to comply with stringent government regulations as well as industry standards.
Mumbai has great infrastructure when it comes to pharma production and a well-developed network of suppliers and distributors, making it the ideal location for pharma companies to operate. Additionally, Mumbai’s close proximity to other major cities like Bangalore and Hyderabad and the availability of skilled labor makes it a very conducive environment for pharma companies.
Which Pharma stock is for long term?
The best pharma stock for long-term investments is subjective, as it depends on individual objectives and risk tolerance. With that said, some of the most popular pharma stocks for long-term investments include AbbVie Inc.
, Eli Lilly & Co. , Johnson & Johnson, Merck & Co. , Pfizer Inc. , and Gilead Sciences. All of these stocks have strong historical records of performance and large, diversified product portfolios.
In addition to the previously mentioned stocks, a few other pharma stocks that make for great long-term investments include Amgen Inc. , Sanofi, Biogen, and Bristol-Myers Squibb. Each of these stocks has variable histories of performance, but are excellent picks for investors with long term goals.
In summary, the best pharma stock for long-term investments comes down to individual criteria and risk profiles. While some may prefer to invest in larger biotech companies, such as Amgen or Biogen, others may prefer more established firms, like Pfizer.
All of the stocks mentioned are long-term picks and can be profitable investments regardless of the company chosen.
Is ONPH a strong buy?
Whether or not ONPH is a strong buy ultimately depends on individual circumstances and personal risk tolerance. Before investing in ONPH, prospective investors should do thorough due diligence to determine if the company is a good fit for their portfolio.
Investors should closely analyze the company’s fundamentals, its past performance, as well as its price-to-earnings ratio. Additionally, investors should consider the industry in which ONPH operates and whether the company is likely to be able to remain competitive.
ONPH is a relatively new entrant into the industry and it faces significant competition for market share. Furthermore, the company is unprofitable, which may make it more difficult for investors to accurately assess the company’s long-term prospects.
For these reasons, some investors may not consider ONPH a strong buy. Ultimately, however, individual investors should determine for themselves if ONPH is a strong buy for their portfolios.
Where is Ajanta Pharmaceuticals located?
Ajanta Pharmaceuticals is located in Mumbai, India. Founded in 1973, Ajanta Pharma is one of India’s leading pharmaceutical companies. Its headquarters are in Mumbai, with operations extending across Africa, Middle East, South and South East Asia, USA and Europe.
Ajanta Pharma manufactures and markets over 1500 formulations from its 8 state-of-the-art manufacturing facilities across India with 9 Research and Development Centers. The company is well known for specialized formulations and exports to over 30 countries in the world.
Ajanta Pharma is committed to building a network of branded generic medicines, responding swiftly and effectively to customer needs to produce world-class products.
